Sedor Pharmaceuticals' Sesquient, or fosphenytoin sodium injection, gained the FDA's nod as a treatment for pediatric and adult status epilepticus. The formulation is room-temperature stable and ready to dilute, and it is indicated for the treatment and prevention of seizures in adults that occur during neurosurgery and as a short-term substitute for oral phenytoin in pediatric patients ages 2 years and older.
FDA OKs injectable fosphenytoin for status epilepticus
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.